Alon Ben-Noon, CEO of NeuroSense Therapeutics
NeuroSense Therapeutics Announces Encouraging Interim Results of Clinical Study in ALS
The study, containing 15 patients, is scheduled to continue for an additional 6 months.
Clinical trials, studies, data, and updates reported in Medical Device News Magazine.